PepGen (PEPG) Insider Mitchell Finer Buys 34,000 Shares
Mitchell Finer joined a wave of insiders picking up 34,000 shares of PepGen Inc. on June 18, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Mitchell Finer bought 34,000 shares of PepGen Inc. ($PEPG) on June 18, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $PEPG is down 4.5% after 1 week, up 22.9% after 1 month and up 45.2% to date (from the $1.79 close on Jun 18, 2026).
PEPG
PepGen Inc.
Key Points
- Mitchell Finer and other company insiders each acquired 34,000 shares of PepGen Inc. on June 18, 2026.
- The stock traded around $1.83, sitting well below its 50-day moving average of $2.67.
- HC Wainwright & Co. maintains a buy rating on the stock with a $20.00 price target as of September 9, 2026.
Get $PEPG trade alerts by text
We text you when insiders, Congress or big funds trade $PEPG. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated PepGen Inc. alert may contain errors. Disclosures
Insider Buying and Selling at PepGen Inc.
Mitchell Finer joined a group of company insiders purchasing stock in PepGen Inc. on June 18, 2026. The transaction involved 34,000 shares. This purchase adds to a notable pattern of insider activity recorded on the exact same date across the biotechnology firm.
Group Purchases Highlighted by Multiple Insiders
The June 18 filing showed parallel transactions by several key individuals associated with the firm. Howard Mayer picked up 34,000 shares on June 18, 2026. Joshua Resnick also acquired 34,000 shares on June 18, 2026, building on prior reports of interest in the clinical-stage biotech. Habib Dable added 34,000 shares on June 18, 2026, while Lisa Wyman secured 34,000 shares on the same day. Each of these transactions shares the identical date and share volume, pointing to coordinated insider positioning.
PepGen Stock Trades Near Lower End of Range
Shares of PepGen changed hands around $1.83. The equity trades below its 50-day moving average of $2.67 and its 200-day moving average of $3.52. The company carries a market capitalization of roughly $196.7 million and a beta of 1.97. The stock has moved within a 52-week window spanning from a low of $1.31 up to a high of $7.80.
Analysts Set New Price Targets
On September 9, 2026, HC Wainwright & Co. reiterated its buy rating on the stock with a price target of $20.00. Craig-Hallum previously maintained a buy rating on PEPG with an $11 price target on June 16, 2026. Across the broader analyst community tracked by consensus figures, the stock stands at a strong buy backed by eight analyst opinions, featuring a mean price target of $10.19. <br>
About the Company and Clinical Pipeline
PepGen Inc. operates as a clinical-stage biotechnology company developing treatments for severe neuromuscular and neurologic conditions. The Boston-based firm focuses on oligonucleotide therapeutics, advancing candidates such as PGN-EDODM1 and FREEDOM2-DM1 in Phase 2 trials for myotonic dystrophy type 1. Founded in 2018, the enterprise employs 57 people and continues to advance its proprietary delivery platforms.
Upcoming Milestones to Watch
Market participants will likely keep track of regulatory updates and clinical trial progress as the pipeline moves forward. Investors will look toward the company's next earnings report scheduled for November 11, 2026, for further updates on its clinical pipeline and financial position.
Related Filing Alerts
Source: Mitchell Finer's Form 4 filing on $PEPG (Jun 18, 2026). Find the original filing: PEPG Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts